The first fresh inflation reading since the government shutdown showed prices unexpectedly eased in November, though the report may not immediately change the Fed’s outlook because of potential distortions in the data. “This looks like positive news overall, but the lack of detail and the absence of data collection during the shutdown introduce a degree of skepticism that’s hard to ignore,” said Olu Sonola, head of US economic research for Fitch Ratings. “We’ll need to wait until next month for a clearer ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Recursion Pharmaceuticals, Inc. (RXRX) has seen a rise in share price, increasing from approximately $4.5 in early October, indicating positive market sentiment towards the company [1]. Company Overview - Recursion Pharmaceuticals is categorized as a TechBio company, focusing on biotechnology and healthcare sectors [1]. - The company is under the coverage of a biotech consultant with over five years of experience in the industry, who has analyzed more than 1,000 companies [1]. Investment Group Insights - The Haggerston BioHealth investing group provides resources for both novice and experienced biotech investors, including catalysts to monitor, buy and sell ratings, and detailed financial forecasts for major pharmaceutical companies [1]. - The group also offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis, which are essential for informed investment decisions in the biotech sector [1].

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ASML, SBGSY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.Past performance is no guarantee of future results. All opinions and data included in this commentary are as of the publication date and are subject to change. The opini ...

Group 1 - The meeting is being recorded for the benefit of shareholders [1] - Participants must consent to the recording and disclose personal information responsibly [2] - The company is now taking over the meeting proceedings [3]

Core Insights - QuantumScape Corp. has achieved a significant milestone by signing a new joint development agreement (JDA) with a top-10 global automaker, marking a key step in its commercial roadmap for 2025 [2][9] - The company has focused on expanding commercial engagement with multiple automakers, indicating growing interest in its solid-state battery technology beyond initial partners like Volkswagen [2][3] Company Developments - Over the past year, QuantumScape has made substantial progress, including expanding its collaboration with Volkswagen's PowerCo and signing JDAs with two major global automakers [3] - The company has also initiated a technology evaluation agreement with another large OEM, suggesting various stages of engagement with multiple automakers [3] - QuantumScape is building a broader ecosystem by partnering with Murata Manufacturing and Corning to develop high-volume ceramic separator production, which is essential for its solid-state battery design [4] Strategic Outlook - Management has described 2025 as a "banner year," focusing on creating a layered commercial pipeline that includes licensing, joint development, and technology validation [5] - With multiple OEMs actively involved, QuantumScape is entering 2026 with increasing industry validation [5] Competitive Landscape - Solid Power is developing long-term relationships with established automakers like BMW and Ford, focusing on all-solid-state battery technology [6] - SES AI is engaging in development partnerships with major automotive OEMs, applying its AI-for-Science platform to innovate new electrolyte materials for EV batteries [7] Market Performance - QuantumScape's shares have surged approximately 145% over the past six months, significantly outperforming the industry [8]

Key Takeaways LMND targets adjusted EBITDA breakeven by 2026, backed by diversification and premium growth.EVER's ROE of 38.2% outperforms the industry, supported by innovation and a debt-free balance sheet.Both LMND and EVER shares have surged 116% YTD, but EVER shows stronger profitability and EPS growth.InsurTechs — technology-led insurers — are trying hard to be game changers, leveraging technologies like AI, telematics, data-driven underwriting and machine learning, among others. Yet, Lemonade Inc. (LM ...

SoFi Technologies is doubling down on cryptocurrency, this time for its commercial clients. ...

Core Insights - The article emphasizes the importance of in-depth research and insights for informed investment decisions in the equity analysis sector, particularly in Latin America [1] Group 1 - The company has over 5 years of experience in equity analysis focused on Latin America [1] - The research provided aims to assist clients in making informed investment decisions [1]

Shares in Birkenstock plunged 9% Thursday after the German shoe retailer warned tariffs will likely weigh heavily on its profit margins.The company – known for its chunky cork sandals – said it expects its annual gross margins will drop by a full percentage point due to US tariffs in the new fiscal year, which runs through Sept. 30, 2026.It expects adjusted earnings before interest, taxes, depreciation and amortization of at least 700 million euros, or roughly $821.8 million, with a margin of 30% to 30.5% – ...